PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Some net income increase while TRAW is negative at -34.49%. John Neff would see a short-term edge over the struggling competitor.
720.76%
Some D&A expansion while TRAW is negative at -27.27%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Deferred tax of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-18.24%
Negative yoy SBC while TRAW is 107.01%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-114.66%
Both reduce yoy usage, with TRAW at -145.03%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Negative yoy AP while TRAW is 231.11%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
139.41%
Some yoy usage while TRAW is negative at -189.23%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-139.67%
Negative yoy while TRAW is 255.84%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-28.06%
Both yoy CFO lines are negative, with TRAW at -22.04%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-383.87%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.